Table 3.
Estimates of anti-HCV prevalence by HIV status.
| Geographic region | HIV+ MSM | HIV– MSM | ||||
|---|---|---|---|---|---|---|
| Record | Participant | Pooled prevalence estimates, % (95% CI) | Record | Participant | Pooled prevalence estimates, % (95% CI) | |
| Asia | 21 | 9,412 | 7.4 (3.8–11.7) | 9 | 19,207 | 5.2 (0.8–12.4) |
| Eastern Asia | 16 | 8,946 | 4.6 (2.9–6.8) | 7 | 17,757 | 0.7 (0.0–2.1) |
| China | 7 | 2,552 | 5.6 (1.7–11.3) | 3 | 16,635 | 0.6 (0.5–0.8) |
| Japan | 1 | 1,068 | 2.1 (1.3–3.0) | |||
| Mongolia | 1 | 50 | 36.0 (23.2–49.9) | |||
| South Korea | 1 | 320 | 4.1 (2.1–6.5) | |||
| Taiwan Province | 7 | 5,006 | 4.7 (2.4–7.6) | 3 | 1,072 | 0.0 (0.0–0.0) |
| South-Eastern Asia | 4 | 366 | 44.9 (0.0–98.8) | 2 | 1,450 | 24.0 (14.4–35.1) |
| Indonesia | 1 | 2 | 100 (30.3–100.0) | 1 | 75 | 30.7 (20.7–41.6) |
| Myanmar | 1 | 177 | 3.4 (1.1–6.7) | |||
| Thailand | 1 | 42 | 19.0 (8.4–32.5) | |||
| Vietnam | 1 | 145 | 84.1 (77.7–89.7) | 1 | 1,375 | 19.9 (17.9–22.1) |
| Western Asia | 1 | 100 | 3.0 (0.4–7.5) | |||
| Turkey | 1 | 100 | 3.0 (0.4–7.5) | |||
| Europe | 45 | 26,997 | 6.3 (5.1–7.6) | 21 | 13,655 | 1.3 (0.7–2.1) |
| Northern Europe | 9 | 1,935 | 4.5 (1.8–8.1) | 7 | 2,893 | 0.4 (0.2–0.8) |
| Denmark | 1 | 84 | 2.4 (0.0–7.0) | 1 | 63 | 0.0 (0.0–0.0) |
| Sweden | 1 | 59 | 13.6 (5.8–23.6) | 2 | 1,056 | 0.1 (0.0–0.6) |
| United Kingdom | 7 | 1,792 | 3.9 (1.1–7.9) | 4 | 1,774 | 0.7 (0.2–1.4) |
| Southern Europe | 8 | 1,278 | 12.7 (5.6–21.9) | 3 | 895 | 3.6 (1.9–5.6) |
| Greece | 1 | 124 | 8.1 (3.8–13.6) | |||
| Italy | 3 | 200 | 22.6 (9.1–39.6) | 1 | 519 | 4.4 (2.8–6.4) |
| Spain | 4 | 954 | 8.1 (3.8–13.6) | 2 | 376 | 3.0 (0.7–6.6) |
| Western Europe | 28 | 23,784 | 5.6 (4.4–7.0) | 11 | 9,867 | 1.4 (0.6–2.5) |
| Belgium | 3 | 509 | 5.0 (2.4–8.3) | 1 | 132 | 0.8 (0.0–3.2) |
| France | 7 | 3,456 | 4.7 (3.4–6.2) | 2 | 2,278 | 1.3 (0.0–8.7) |
| Germany | 4 | 3,084 | 12.4 (6.5–19.8) | 2 | 3,702 | 4.1 (0.0–22.7) |
| Netherlands | 7 | 4,936 | 5.8 (2.2–10.6) | 5 | 2,934 | 1.4 (0.4–3.0) |
| Switzerland | 7 | 11,799 | 3.8 (2.9–4.8) | 1 | 821 | 0.4 (0.0–0.9) |
| Africa | 5 | 770 | 10.6 (2.9–21.5) | 4 | 1,898 | 4.6 (1.9–8.4) |
| Northern Africa | 1 | 12 | 83.3 (56.1–99.6) | 1 | 215 | 4.2 (1.9–7.3) |
| Libya | 1 | 12 | 83.3 (56.1–99.6) | 1 | 215 | 4.2 (1.9–7.3) |
| Southern Africa | 2 | 605 | 4.3 (2.1–7.0) | 1 | 426 | 2.3 (1.1–4.0) |
| South Africa | 2 | 605 | 4.3 (2.1–7.0) | 1 | 426 | 2.3 (1.1–4.0) |
| Western Africa | 2 | 153 | 3.6 (0.7–7.8) | 2 | 1,257 | 6.3 (0.8–16.3) |
| Burkina Faso | 1 | 10 | 10.0 (0.0–38.1) | 1 | 319 | 11.0 (7.8–14.7) |
| Nigeria | 1 | 143 | 4.9 (1.9–9.1) | 1 | 938 | 3.0 (2.0–4.2) |
| Northern America | 17 | 13,099 | 11.4 (8.9–14.2) | 12 | 9,411 | 4.4 (2.2–7.2) |
| Canada | 4 | 1,409 | 11.2 (4.7–20.1) | 3 | 746 | 2.8 (1.6–4.2) |
| United States | 13 | 11,690 | 11.5 (8.7–14.7) | 9 | 8,665 | 4.6 (2.0–8.2) |
| Latin | ||||||
| America/Caribbean | 3 | 246 | 20.1 (11.8–29.8) | 1 | 410 | 3.2 (1.7–5.1) |
| Central America | 1 | 61 | 18.0 (9.3–28.8) | |||
| Mexico | 1 | 61 | 18.0 (9.3–28.8) | |||
| South America | 2 | 185 | 21.0 (8.4–37.3) | 1 | 410 | 3.2 (1.7–5.1) |
| Argentina | 2 | 185 | 21.0 (8.4–37.3) | 1 | 410 | 3.2 (1.7–5.1) |
| Oceania | 3 | 4,006 | 11.6 (10.6–12.6) | 2 | 1,356 | 2.2 (0.1–6.5) |
| Australia | 3 | 4,006 | 11.6 (10.6–12.6) | 2 | 1,356 | 2.2 (0.1–6.5) |
| Global | 94 | 54,530 | 8.1 (6.8–9.4) | 49 | 45,937 | 2.8 (1.9–4.0) |
HCV, hepatitis C virus; CI, confidence interval; HIV, human immunodeficiency virus; MSM, men who have sex with men. Bold values represent results at the global or regional level, and non-bold values represent results at national level.